Method of eosinophil depletion with antibody to CCR 3 receptor
US6207155A · kind A · utility
5Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 1998 |
| Grant date | Mar 27, 2001 |
| Priority date | — |
| Expiry date | May 6, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Binding compositions and various methods of use of the binding compositions are provided. In particular, a method is provided which comprises administering an effective amount of the binding composition, alone or in combination with other compounds, to eosinophils, thereby reducing the level of eosinophils in an individual. Preferably, the binding composition is a monoclonal antibody specific for CCR3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.